Skip to main content

Webinar: Myths and misconceptions of Premenstrual Dysphoric Disorder

3 March 2023

woman applying mascara in the mirror

This blog contains reference to suicide.

Only recognised by the World Health Organisation in 2019, PMDD is a severely under-researched condition. Our researchers at NCMH and Cardiff University are pleased to be working with charity partners to raise awareness, reduce the stigma and improve support for the condition.

Professor Arianna di Florio from the National Centre for Mental Health at Cardiff University is currently leading PreDDICT (premenstrual dysphoric disorder – indicators, causes and triggers) a new research study that endeavours to discover more about PMDD to improve diagnosis, intervention, and treatment.

The webinar, which discussed various misconceptions surrounding PMDD, was attended by people from all over the world. Professor di Florio offered a data/ research led perspective, and we welcomed Laura Murphy, Director of Education and Awareness from the IAPMD who shared her own lived experience of the condition and her work with the organisation.

NCMH psychology assistant Chloe Apsey, who is also working on PreDDICT, provided a general overview of PMDD and the menstrual cycle:

"The phase of the menstrual cycle where most people begin to experience symptoms of PMDD is the luteal phase – the days between ovulation and menstrual bleeding – lasting twelve to fourteen days and characterised by high levels of progesterone."

PMDD symptoms can include:

  • Depression or severe low mood
  • Anxiety
  • Decreased interest in usual activities (such as work, school, interacting with friends, and hobbies)
  • Lethargy, becoming easily fatigued, or a lack of energy
  • Hypersomnia or insomnia

Chloe Apsey also noted that though PMDD can impact anyone who experiences a menstrual cycle, most of the literature that will be discussed recruited participants who identify as women. The IAPMD provide further information regarding the experiences of transgender people with PMDD.

Professor di Florio then introduced Laura Murphy from IAPMD and invited her to share her own experiences of the condition.

“I was seventeen years old when I first started the contraceptive pill, and on day twenty-one when I stopped taking it for the required break, I believe my hormone levels dropped significantly and my mental health hit the floor,” Laura noted of her first experiences of hormonal mental ill-health.

"It was a running joke in my university house that I could get angry, tired, and irritable around the time of my period. But I never really made that link between my cycle and my mood".

Professor di Florio asked Laura what led her to think that she was experiencing PMDD.

“PMDD was first picked up on by my counsellor, which led to numerous GP visits and symptom dismissals.

“I’d spent a lot of time accepting my symptoms as just the way I am, that I just couldn’t cope with life like everyone else, that I’m broken”.

After researching PMDD, Laura discovered resources and community support.

"It was validating to know there were others like me. My story is not unique, there are others who have gone through the same as me".

Professor di Florio then asked Laura what treatments she was offered upon diagnosis, and she described the effectiveness of the treatment available for PMDD, including her experience of surgery.

“I’d already lost a lot of years to PMDD, and I wanted to take some time back for myself. It was literally, the only thing left for me to try”.

Does PMDD exist?

Professor di Florio referenced the World Health Organisation and diagnostic systems that identify and classify diseases and mental health disorders, such as the DSM-5, an internationally recognised manual for assessing and diagnosing mental disorders, alongside lived experience accounts (such as Laura’s) when discussing the existence of PMDD.

"Those who believe that PMDD does not exist maintain that this is because PMDD is a cultural-bound phenomenon with a strong societal basis".

However, Professor di Florio presented a world map displaying symptom recording locations, noting that "although non-Western cultures typically refer to symptoms as PMS, the rates itself are very similar- if not higher- than those of similar studies conducted in the West.”

Is the response to hormonal changes always the same?

“It is important to note that all people are different, and the same hormonal changes can trigger different responses according to the person’s sensitivities which can change over time. One size does not fit all here."
Professor Arianna Di Florio Professor, Division of Psychological Medicine and Clinical Neurosciences

Professor di Florio used studies from the Royal College of Obstetrics and Gynaecology to illustrate this change, and noted that "perhaps PMDD should be referred to as a plural term to acknowledge the differing of symptoms."

In response to this, Laura highlighted a webinar from the IAPMD that discusses the sub-types of PMDD, adding that “symptoms can appear at any point throughout the reproductive life”.

“Tracking symptoms is key to unpicking what is going on,” she continued, directing viewers to a self-screener toolkit on the IAPMD website.

Is PMDD associated with suicidality?

“Whilst suicidality is not listed amongst the symptoms of PMDD, the literature suggests that those with PMDD are at a risk of suicidality,” Professor di Florio noted, referencing various studies that conclude higher suicide rates of women with PMDD.

However, Professor di Florio notes that to compare this with the rates of general suicidality is more difficult as there would need to be a specific PMDD and suicidality survey.

What is the future of research in PMDD?

Professor di Florio noted that the PreDDICT survey uses DNA and genetics which is fixed at birth, meaning participants do not necessarily need to be experiencing symptoms at present, but may have in the past. Additionally, DNA can be collected as easily as providing a saliva sample.

She continued, “Using DNA can offer clues into the biology of PMDD. Many variations with small effects influence the risk of developing common disorders."

Watch the webinar and Q&A

Share this story